Every 8-K that Vivani Medical, Inc. (VANI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VANI filings page.
Vivani Medical, Inc. (VANI) reports under Regulation FD that it has a definitive agreement and plan of merger involving its wholly owned subsidiary Cortigent, Inc., ClearOne, Inc., and CLRO Merger Sub, Inc., under which Cortigent will merge with and into Merger Sub and become a wholly owned subsidiary of ClearOne (the Transaction).
Vivani states that it currently anticipates the pricing and closing of the Transaction will occur in October 2026. The company characterizes related statements as forward-looking and highlights that risks, including an inability to consummate the Transaction, are discussed in its annual and quarterly reports filed with the SEC.
Vivani Medical, Inc. filed a Form 8-K to furnish an investor slide presentation under Item 7.01 (Regulation FD Disclosure). The company states that it periodically presents and distributes these slides to the investment community at conferences to provide business updates.
The slide deck, titled “Vivani Medical, Inc. slide presentation” and dated August 17, 2026, is included as Exhibit 99.1. Vivani clarifies that this information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated into Securities Act or Exchange Act filings unless expressly referenced.
Vivani Medical, Inc. reported second-quarter 2026 results and highlighted clinical and strategic progress. All 20 participants in the SLIM-1 Phase 1 trial of NPM-139, a miniature ultra long-acting semaglutide implant for chronic weight management, were enrolled and successfully dosed ahead of schedule, with top-line data expected in November 2026. Vivani also signed a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal technology, and its Cortigent subsidiary entered a definitive merger with Nasdaq-listed ClearOne to form Cortigent Holdings, anticipated to trade under ticker CRGT in the third quarter of 2026.
As of June 30, 2026, Vivani held $20.8 million in cash, cash equivalents and restricted cash, up from $17.6 million at year-end 2025, supported by prior share purchase agreements and January 2026 financings. Second-quarter 2026 research and development expense was $4.5 million and general and administrative expense was $2.4 million, both modestly lower than a year earlier. Net loss for the quarter narrowed to $6.4 million from $7.1 million, with other income of $0.5 million.
Vivani Medical, Inc. reports full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1 trial of NPM-139, a miniature, subdermal semaglutide implant for chronic weight management. The randomized, controlled trial evaluates safety, tolerability and pharmacokinetics versus low-dose Wegovy injection in GLP-1 naïve participants in Australia.
NPM-139 uses Vivani’s NanoPortal implant platform, which is being designed to deliver semaglutide continuously for six to twelve months and to allow rapid reversal of drug exposure when needed. SLIM-1 runs over four weeks, with top-line data from the 20-participant study expected in November 2026 and anticipated to inform a planned Phase 2 dose-ranging trial in 2027. Vivani also highlights preclinical studies showing sustainable 20% weight reduction in animal models and a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and the NanoPortal technology.
Vivani Medical, Inc. furnished an investor slide presentation used at the Emerging Growth Conference in New York on July 15, 2026 at 4:10 p.m. Eastern Time. The presentation, delivered by CEO Dr. Adam Mendelsohn, includes an update that the company’s first dosing of SLIM-1 is expected in August 2026.
The information in the presentation is provided under Regulation FD, is not deemed filed or subject to liability under Section 18 of the Exchange Act, and is not incorporated by reference into other securities law filings unless expressly referenced.
Vivani Medical, Inc. reports that its wholly owned subsidiary Cortigent, Inc. has signed an Agreement and Plan of Merger with ClearOne, Inc., under which Cortigent will merge into a ClearOne subsidiary and become a wholly owned ClearOne unit. Vivani’s Cortigent equity will be converted at closing into 12,500,000 shares of ClearOne common stock, while ClearOne must complete a concurrent Form S-1 financing of $10,000,000 to $15,000,000 through 2,500,000 to 5,000,000 units, each with one share and a warrant exercisable at $10.00. The merger is subject to stockholder approvals, Nasdaq listing conditions, completion of the financing and other customary closing conditions, and includes a breakup-fee mechanism capped at $250,000. Vivani also announces a separate non-exclusive agreement with Novo Nordisk, allowing Novo Nordisk to internally evaluate Vivani’s NPM-139 semaglutide NanoPortal implant for chronic weight management, alongside plans to start a Phase 1 first-in-human study with Wegovy injections as an active comparator in mid-2026.
Vivani Medical held its 2026 annual stockholder meeting and approved an amended 2022 Omnibus Incentive Plan that increases the common shares reserved for equity awards by 11,000,000, from 10,033,333 to 21,033,333 shares. Stockholders also re-elected six directors, approved executive compensation on a non-binding advisory basis, and ratified BPM LLP as auditor for the year ending December 31, 2026. The meeting reached a quorum with 62,071,530 of 86,235,104 common shares represented in person or by proxy.
Separately, Vivani received approval from Bellberry, a human research ethics committee in Australia, to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant for obesity and chronic weight management. SLIM-1 is designed as an open-label, randomized, active comparator-controlled trial evaluating low-dose NPM-139 versus Wegovy 0.25 mg/week over four weeks in obese or overweight subjects, with 10 participants per group, focusing on safety, tolerability, and pharmacokinetics while also measuring weight loss.
Vivani Medical, Inc. is providing an informational update by sharing an investor slide presentation in connection with its appearance at the Jefferies Global Healthcare Conference in New York. The company plans to present on June 4, 2026 at 11:05 a.m. Eastern, and the slides are available as Exhibit 99.1 and on the Investors section of its website.
The company notes that the slide deck speaks only as of its date and that Vivani has no obligation to update it, even if circumstances change. The information in this communication is being furnished under Regulation FD and is not deemed filed for liability purposes under the securities laws.
Vivani Medical reported first quarter 2026 results, highlighting a net loss of $6.8 million compared with $6.3 million a year earlier, and ending the period with $19.7 million in cash and cash equivalents. Total assets were $42.4 million and stockholders’ equity was $19.1 million.
Operating expenses rose modestly as research and development reached $4.4 million and general and administrative expenses were $2.4 million, each up about 4% year over year. The company used $6.2 million in operating cash during the quarter and raised $9.7 million through a registered direct offering and other securities purchase agreements, contributing to an expected cash runway through the first half of 2027 while it advances its GLP‑1 implant SLIM‑1 Phase 1 trial and prepares a potential Phase 2 study.
Vivani Medical, Inc. reported fourth quarter and full year 2025 results, highlighting progress on its GLP‑1 implant pipeline and funding. The company advanced NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management, supported by first-in-human LIBERATE-1 data and year-long preclinical results showing sustained semaglutide exposure and more than 20% sham-adjusted weight loss after a single implant.
Vivani plans to start a Phase 1 feasibility study of NPM-139 in Australia in mid-2026, with initial data anticipated by year-end 2026, and aims to follow with a Phase 2 study. It is also exploring a separation of neuromodulation subsidiary Cortigent into an independent, publicly traded company. For 2025, the company reported a net loss of $26,609 thousand, or $0.43 per share, on operating expenses of $27,556 thousand. Cash and cash equivalents were $16,232 thousand as of December 31, 2025, and combined cash, equivalents and commitments are expected to fund operations into mid‑2027 after raising $41 thousand in recent financings.
Vivani Medical, Inc. entered into two equity transactions on January 25, 2026. The company agreed to sell 1,351,351 common shares in a private placement to an entity affiliated with its board chairman at $1.48 per share, generating gross proceeds of about $2.0 million with no warrants, discounts, or placement fees. At the same time, Vivani arranged a registered direct offering of 1,689,200 common shares expected to raise roughly $2.5 million in gross proceeds under its existing shelf registration, paying a 7% cash fee to the placement agent plus up to $125,000 of expenses. Directors and officers agreed to a 60-day lock-up after the registered offering closes, limiting insider share sales during that period.
Vivani Medical, Inc. furnished an 8-K announcing a business update and third quarter 2025 financial results via a press release, and provided a corporate slide presentation. The materials were furnished under Items 2.02 and 7.01 on November 13, 2025 and are available as Exhibits 99.1 (press release) and 99.2 (slides).
The company noted these materials are not deemed “filed” under the Exchange Act. Vivani also posted the current slide deck to the Investors section of its website.
Vivani Medical (VANI) secured new capital through two equity transactions. The company completed a private placement of 3,703,703 common shares at $1.62 per share, generating approximately $6.0 million in gross proceeds. No warrants, discounts, or placement fees were involved.
Concurrently, Vivani entered a registered direct offering for 6,000,000 common shares, with gross proceeds of approximately $9.7 million, before a 7.0% placement fee and up to $125,000 of reimbursable expenses paid to ThinkEquity. Directors and officers agreed to 60-day lock-ups from the closing of the registered offering. The registered sale is being made under the company’s effective Form S-3 shelf via a prospectus and prospectus supplement.
Vivani Medical, Inc. reported that it has temporarily withdrawn the previously announced October 8, 2025 record date for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The change was announced on October 3, 2025 and is attributed to delays arising from the current shutdown of the U.S. federal government.
Cortigent is developing brain implant devices using neuromodulation technology, and the spin-off remains proposed, but the timing of determining which shareholders would be eligible to receive shares is now on hold until a new record date is set.
Vivani Medical, Inc. is moving forward with its previously announced spin-off of its wholly owned subsidiary, Cortigent, Inc., which develops brain implant devices using neuromodulation technology. The company has set October 8, 2025 as the record date for the transaction. Stockholders who hold Vivani common stock as of that date will be entitled to receive Cortigent common stock when the spin-off is completed. The company stated that the distribution date and the share dividend ratio for Cortigent stock will be announced at a later time. Vivani also issued a press release on September 17, 2025, describing this update.
Vivani Medical, Inc. filed a current report to furnish its latest corporate slide presentation to the investment community. The slide deck, dated September 9, 2025, is attached as Exhibit 99.1 and is also available in the Investors section of the company’s website.
The slides are provided under Regulation FD as investor information and are deemed “furnished,” not “filed,” which limits their use for certain securities law liability purposes. Vivani notes the slides speak only as of their date and expressly disclaims any obligation to update them.
Vivani Medical, Inc. announced on September 4, 2025 that it has outlined clinical development plans for NPM-139, its investigational semaglutide implant intended for chronic weight management in patients who are obese or overweight with a related comorbidity. The disclosure is furnished as an exhibit (Press Release, Exhibit 99.1) to this Current Report and does not include financial metrics, timelines, enrollment targets, regulatory milestones, or expected costs. The filing is signed by Donald Dwyer, Chief Business Officer.
Vivani Medical entered a Share Purchase Agreement effective August 11, 2025 to sell 7,936,507 shares of common stock at $1.26 per share, the last reported sale price on that date. The placement is expected to generate approximately $10.0 million in gross proceeds to the Company, with issuances occurring over multiple closings through July 15, 2026, each subject to closing conditions.
The Company stated that no warrants or discounts were provided and that no placement agent or investment banking fees were incurred. The Shares will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506 of Regulation D and have not been registered for resale. The filing attaches a Share Purchase Agreement and a press release and corporate slide presentation as exhibits.
Vivani Medical, Inc. (Nasdaq: VANI) filed a Form 8-K to disclose the voting results of its 24 June 2025 Annual Meeting of Stockholders. A quorum was achieved with 37.1 million of 59.2 million outstanding shares represented. All six director nominees—Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn and Daniel Bradbury—were elected, each receiving roughly 25 million votes in favor versus approximately 0.4-0.6 million withheld, and 11.8 million broker non-votes. Stockholders also (1) ratified BPM LLP as independent auditor for fiscal 2025 with 36.5 million votes in favor and minimal opposition, and (2) approved, on a non-binding basis, executive compensation with 23.1 million votes for, 0.6 million against, 1.7 million abstentions and 11.8 million broker non-votes. No other matters were presented.